Present and Future Therapies for Chronic Hepatitis B

Area of Science:

• Hepatology
• Virology
• Immunology

Background:

• Chronic hepatitis B (CHB) is a leading cause of liver-related morbidity and mortality worldwide.
• Untreated CHB can lead to severe end-stage liver diseases such as liver failure, cirrhosis, and hepatocellular carcinoma (HCC).
• High levels of serum HBV DNA are significantly associated with the progression to severe liver disease.

Purpose of the Study:

• To discuss standard and optimized antiviral therapies for CHB in treatment-naïve and experienced patients.
• To review antiviral treatments for special populations with CHB.
• To explore recent advancements in developing new anti-HBV agents.

Main Methods:

• Review of current antiviral therapies including nucleoside/nucleotide analogues (NAs) and interferon-α (IFN-α).
• Discussion of treatment strategies for different patient groups.
• Examination of novel therapeutic agents targeting viral life cycle and host immune responses.

Main Results:

• Current antiviral drugs effectively suppress HBV replication and reduce liver disease progression.
• Optimized therapies and new agents hold promise for improved long-term outcomes.
• Combination therapies are being developed to target multiple aspects of HBV infection.

Conclusions:

• Antiviral therapy is crucial for managing CHB and preventing severe liver complications.
• Ongoing research into new anti-HBV agents and combination therapies aims for eventual HBV eradication.
• Future strategies involve targeting diverse steps of the viral life cycle and modulating host immunity.